Format

Send to

Choose Destination
Neuron. 2019 Mar 6;101(5):774-778. doi: 10.1016/j.neuron.2019.02.005.

Ketamine: A Paradigm Shift for Depression Research and Treatment.

Author information

1
Departments of Psychiatry, Neuroscience, and Psychology, Yale University, New Haven, CT, USA; National Center for PTSD, VA Connecticut Healthcare System, West Haven, CT, USA; Yale-New Haven Hospital, New Haven, CT, USA. Electronic address: john.krystal@yale.edu.
2
Departments of Psychiatry, Neuroscience, and Psychology, Yale University, New Haven, CT, USA; National Center for PTSD, VA Connecticut Healthcare System, West Haven, CT, USA.
3
Departments of Psychiatry, Neuroscience, and Psychology, Yale University, New Haven, CT, USA; Yale-New Haven Hospital, New Haven, CT, USA; Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA.
4
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
5
Departments of Psychiatry, Neuroscience, and Psychology, Yale University, New Haven, CT, USA; National Center for PTSD, VA Connecticut Healthcare System, West Haven, CT, USA; Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA.

Abstract

Ketamine is the first exemplar of a rapid-acting antidepressant with efficacy for treatment-resistant symptoms of mood disorders. Its discovery emerged from a reconceptualization of the biology of depression. Neurobiological insights into ketamine efficacy shed new light on the mechanisms underlying antidepressant efficacy.

PMID:
30844397
PMCID:
PMC6560624
[Available on 2020-03-06]
DOI:
10.1016/j.neuron.2019.02.005

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center